Sarissa Capital Management LP reported 10 holdings worth US$153M as of Sep 30, 2026 (Form 13F)
As of Sep 30, 2026 · Filed Nov 16, 2026
Sarissa Capital Management LP reported 10 holdings worth US$153M as of Sep 30, 2026. Largest: Innoviva, Inc., Ironwood Pharmaceuticals, Inc. and Amarin Corporation plc. Filed Nov 16, 2026 (Form 13F).
- Holdings
- 10
- Value as reported
- US$153M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|---|---|---|
| Innoviva, Inc. | 1.89M | US$40.1M | 26.2% |
| Ironwood Pharmaceuticals, Inc. | 9.19M | US$36.5M | 23.8% |
| Amarin Corporation plc | 1.29M | US$16.7M | 10.9% |
| Lantheus Holdings, Inc. | 167K | US$16.6M | 10.8% |
| Neurocrine Biosciences, Inc. | 117K | US$16.5M | 10.8% |
| Cytokinetics, Incorporated | 229K | US$15.1M | 9.8% |
| Biohaven Ltd. | 582K | US$7.77M | 5.1% |
| Regeneron Pharmaceuticals, Inc. | 4,190 | US$3.18M | 2.1% |
| Vor Biopharma Inc. | 25,399 | US$485K | 0.32% |
| Biogen Inc. | 950 | US$215K | 0.14% |
Source
Download original · View original at SEC